VCs Raise Cash For New Deals; Five Biotechs Find Funding

Venture capitalists raised $12bn for new US-based funds in the first quarter of 2016, including a handful of VC firms that invest in biotechnology, which is good news for early-stage drug developers that hope to close new funding rounds, like their peers at Entasis Therapeutics did recently.

Venture capitalists raised $12bn for new US-based funds in the first quarter of 2016, including a handful of VC firms that invest in biotechnology, which is good news for early-stage drug developers that hope to close new funding rounds, like their peers at Entasis Therapeutics did recently.

The National Venture Capital Association (NVCA) reported that 57 VC firms in the US raised new funds during the first...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category